A5032745734- Skin and Cellular Biology Research
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Nail Diseases and Treatments
- Psoriasis: Treatment and Pathogenesis
- Cutaneous lymphoproliferative disorders research
- Tumors and Oncological Cases
- Poxvirus research and outbreaks
- Food Allergy and Anaphylaxis Research
- Genetic and rare skin diseases.
- Autoimmune and Inflammatory Disorders Research
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- melanin and skin pigmentation
- Nonmelanoma Skin Cancer Studies
- Histiocytic Disorders and Treatments
- Hair Growth and Disorders
- Neonatal skin health care
- Eosinophilic Disorders and Syndromes
- Autoimmune and Inflammatory Disorders
- Dermatological and Skeletal Disorders
- Herpesvirus Infections and Treatments
- Medicine and Dermatology Studies History
- Vascular Malformations and Hemangiomas
- Contact Dermatitis and Allergies
The University of Texas Health Science Center at San Antonio
2013-2025
The University of Texas Health Science Center at Houston
2019-2025
Baylor College of Medicine
2003-2024
Texas Dermatology and Laser Specialists
2017-2024
Children's Hospital of San Antonio
2015-2023
Leo Pharma (Australia)
2023
Mayne Pharma (Australia)
2023
Almirall (Spain)
2023
Bristol-Myers Squibb (Switzerland)
2023
Novartis (Switzerland)
2023
For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe atopic dermatitis (AD), 16 weeks of treatment dupilumab resulted in substantial clinical benefit compared placebo, an acceptable safety profile. However, long-term data on the approved dose regimens adolescents AD are lacking. This open-label extension study (LIBERTY PED-OLE, NCT02612454) reports safety, efficacy, and pharmacokinetics who had participated parent trials. Patients enrolled under original...
BackgroundTapinarof cream 1% once daily (QD), a topical aryl hydrocarbon receptor agonist, downregulates pro-inflammatory Th2 cytokines, upregulates skin-barrier components, and reduces oxidative stress.ObjectiveTo assess tapinarof efficacy safety in adults children down to 2 years of age with atopic dermatitis (AD).MethodsEight hundred thirteen patients were randomized or vehicle QD two 8-week phase 3 trials.ResultsThe primary endpoint, Validated Investigator Global Assessment for Atopic...
Abstract Background Acne‐induced hyperpigmentation (AIH) may accompany acne vulgaris (AV) inflammation in all skin phototypes. Trifarotene has shown depigmenting properties vivo. This study evaluated trifarotene plus skincare because it is increasingly recognized that holistic AV management should include and treatments. Methods a phase IV double‐blind, parallel‐group of patients (13–35 years) with moderate AIH treated ( N = 60) or vehicle 63) regimen (moisturizer, cleanser, sunscreen) for...
Aplasia cutis congenita (ACC) refers to any condition in which there is absence of skin at birth. This can be isolated ACC occurring on the scalp, with or without underlying ectopic neural tissue, associated other conditions such as Adams-Oliver syndrome epidermolysis bullosa. We discuss different types and anomalies along an approach diagnosis management.
About 1% of children and adolescents worldwide are affected by plaque psoriasis.To evaluate the long-term efficacy safety ixekizumab for pediatric patients with moderate to severe psoriasis.This multicenter randomized clinical trial (IXORA-PEDS) evaluated psoriasis. Participants were aged 6 years younger than 18 years; had psoriasis, which was defined as Psoriasis Area Severity Index (PASI) 12 or higher, static Physician's Global Assessment (sPGA) score 3 psoriasis-affected body surface area...
<h3>Importance</h3> Molluscum contagiosum (MC) is a highly contagious skin condition. Lesions may persist for months to years, and no US Food Drug Administration–approved medications are currently available in the US. <h3>Objective</h3> To assess efficacy safety of berdazimer gel, 10.3%, novel topical nitric oxide–releasing medication, treatment MC. <h3>Design, Setting, Participants</h3> This was multicenter, vehicle-controlled, double-blind, phase 3 randomized clinical trial (B-SIMPLE4)...
<h3>Background</h3> An out-of-office therapeutic agent indicated for molluscum contagiosum is needed. <h3>Objective</h3> To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide–releasing medication) versus vehicle. <h3>Methods</h3> Berdazimer or vehicle was applied once daily to all lesions 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance partial at week 12. Safety tolerability adverse events through 24...
<h3>Importance</h3> Children with epidermolysis bullosa (EB) comprise a rare population high morbidity and mortality. An improved understanding of the clinical trajectory patients EB, including age at time diagnosis major events, is needed to refine best practices improve quality life outcomes for EB. <h3>Objectives</h3> To describe demographics, characteristics, milestone diagnostic events (such as initial esophageal dilation), in EB using Epidermolysis Bullosa Clinical Characterization...
Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy was well tolerated patients down to age 2 years with AD. Here, we evaluate patient-reported outcomes (PROs), including family impact, ADORING 2. 2, 813 were randomized or vehicle QD 8 weeks. PROs assessed using Dermatology Life Quality Index (DLQI), Children's...
Introduction: In ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA®, Dermavant Sciences, an Organon Company) once daily (QD) demonstrated superior efficacy was well tolerated in patients down to age years with atopic dermatitis (AD). We present efficacy, safety, tolerability from 3. Methods: Patients 2, a 4-week maximal usage pharmacokinetics trial, tapinarof-naive mild AD, or moderate severe that did not meet inclusion criteria, received QD for up 48 weeks. Endpoints included...
<h3>Background</h3> Tufted angioma (known in Japanese literature as angioblastoma of Nakagawa) is an uncommon, histologically benign, vascular tumor. Lesions typically present during infancy or early childhood and are most commonly reported to persist and/or expand over time. Congenital presentations rare, reports spontaneous regression. <h3>Observations</h3> We a series 5 histopathologically confirmed cases congenital tufted that spontaneously regressed childhood. also review the...
Abstract Introduction Tapinarof cream 1% once daily (QD) demonstrated efficacy versus vehicle and was well tolerated in adults adolescents with moderate to severe atopic dermatitis (AD) a previously reported phase 2 trial. Objective Here, we report pivotal 3 safety results for tapinarof QD the treatment of children down years age AD. Materials Methods ADORING 1 were two identical 3, randomized, double-blind, vehicle-controlled trials. Eligibility criteria included Validated Investigator...
Abstract Background Roflumilast is a highly potent phosphodiesterase 4 inhibitor under investigation as non-steroidal, once-daily cream for atopic dermatitis (AD). Methods INTEGUMENT-PED (NCT04845620) was Phase 3 parallel-group, double-blind, vehicle-controlled trial. Children aged 2 to 5 years with mild moderate AD were treated roflumilast 0.05% (n=437) or vehicle (n=215) weeks. The primary efficacy endpoint validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) Success...
Introduction: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA®, Dermavant Sciences, Inc.) once daily (QD) demonstrated significant efficacy was well tolerated in patients down to age years with atopic dermatitis (AD). We present efficacy, safety, tolerability outcomes from 3. Methods: Eligible 1, 2, a 4-week maximal usage pharmacokinetics trial, tapinarof-naive mild, or moderate severe AD, that did not meet eligibility criteria for received QD up 48 weeks. Efficacy endpoints...
Abstract Background/Objectives Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected bacteria. A subset EB patients at risk for squamous cell carcinoma, and bacterial‐host interactions have been considered in this risk. The Clinical Characterization Outcomes Database serves as a repository information from multiple centers the United States Canada. Access to resource enabled broad‐scale analysis wound cultures. Methods retrospective 739 cultures 158...
In the past pyogenic granuloma (PG) in infancy has been easily confused clinically and histopathologically with infantile hemangioma (IH). 2000 North colleagues discovered that IH is immunopositive for GLUT-1, a glucose transporter which also expressed placental capillaries (1). GLUT-1 staining negative granuloma. We report two newborns congenital disseminated PG who were otherwise healthy. both of these cases, supported proper diagnosis.